Leukemia ECOG 2905

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risks MDS and Symptomatic Anemia – temporarily suspended to accrual.